NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Gartlehner G, Hansen RA, Thieda P, et al. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Jan. (Comparative Effectiveness Reviews, No. 7.)
This publication is provided for historical reference only and the information may be out of date.
Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression [Internet].
Show detailsEvidence Table 1. KQ1: Efficacy or effectiveness of antidepressants for treating depressive symptoms
Evidence Table 4. KQ4: Safety, adverse events or adherence of antidepressants
Evidence Table 5. KQ4: Systematic reviews and meta-analyses on safety, adverse events, or adherence
Evidence Table 6. KQ5: Efficacy, effectiveness, or harms of antidepressants in subpopulations
Evidence Table 7. KQ5: Systematic reviews and meta-analyses on antidepressants in subpopulations
MMA Abbreviations for Evidence Tables
| A/S | Aktieselskap (Company type in Denmark) |
| AD | antidepressant |
| AE | adverse event |
| AIDS | acquired immune deficiency syndrome |
| AMT | awake and moving time |
| ARV | antiretroviral |
| ATVI | aortic time velocity interval |
| BDI | Beck Depression Inventory |
| BMI | body mass index |
| BP | blood pressure |
| BQOL | Battelle Quality of Life Measure |
| BSI | Brief Symptom Inventory of Depression |
| BUP SR | bupropion sustained release |
| BUP | bupropion |
| CBT | cognitive-behavioral therapy |
| CDC | Centers for Disease Control and Prevention |
| CESD | Center for Epidemiologic Studies-Depression |
| CGI | Clinical Global Impressions |
| CGI-I | Clinical Global Impressions Improvement Scale |
| CGI-S | Clinical Global Impressions Severity Scale |
| CI | confidence interval |
| CIT | citalopram |
| cm | centimeter |
| CR | controlled release |
| D | drug |
| DBP | diastolic blood pressure |
| DESS | Discontinuation-Emergent Signs and Symptoms checklist |
| df | degrees of freedom |
| diff | difference(s) |
| DSM | Diagnostic and Statistical Manual of Mental Disorders |
| DSM-III | Diagnostic and Statistical Manual of Mental Disorders, version III |
| DSM-III-R | Diagnostic and Statistical Manual of Mental Disorders, version III revised |
| DSM-IV | Diagnostic and Statistical Manual of Mental Disorders, version IV |
| DSP | deliberate self-poisoning |
| DUL | duloxetine |
| ECG | electrocardiogram |
| ECT | Electroconvulsive therapy |
| EEG | electroencephalogram |
| ESC | escitalopram |
| FDA | Food and Drug Administration |
| FLUO | fluoxetine |
| FLUV | fluvoxamine |
| FSQ | Functional Status Questionnaire |
| GBS | Gottfrey-Brane-Steen |
| GDS | Geriatric Depression Scale |
| GP | general physician |
| GPRD | General Practice Research Database |
| HAM-A | Hamilton Rating Scale for Anxiety |
| HAM-D | Hamilton Rating Scale for Depression |
| HIV | Human immunodeficiency virus |
| HSCL-D | Hopkins Depression Scale |
| HTN | hypertension |
| ICD10 | International Classification of Diseases- 10th revision |
| IDS | Inventory for Depressive Symptomatology |
| IDS-C | Inventory for Depressive Symptomatology - Clinician Rated |
| IDS-SR | Inventory for Depressive Symptomatology - Self Rated |
| IMI | imipramine |
| IR | immediate release |
| ITT | intent to treat |
| KQ | key question |
| LOCF | last-observation-carried-forward |
| LTF | loss to follow-up |
| MADRS | Montgomery Asberg Depression Rating Scale |
| MAF | Multidimensional |
| MAOI | monoamine oxidase inhibitor |
| m-CPP | meta-chlorophenylpiperazine |
| MD | medical doctor |
| MDD | major depressive disorder |
| MI | myocardial infarction |
| mil | milnacipran |
| MINI | Mini International Neuropsychiatric Interview |
| MIR | mirtazapine |
| mmHG | millimeters of mercury |
| MMSE | Mini Mental State Examination |
| mo | month(s) |
| N | number |
| N/A | not applicable |
| NEF | nefazodone |
| NIH | National Institute of Health |
| NIHM | Health Diagnostic Interview Schedule |
| NIMH | National Institute of Mental Health |
| NNT | number needed to treat |
| NoVASC | no other comorbid vascular illness |
| NR | not reported |
| NS | not sig |
| NV | Naamloze Vennootschap (Dutch company type) |
| OR | odds ratio |
| P | P-value |
| PAR | paroxetine |
| PCP | primary care physician |
| PGI | Patient Global Impression |
| PGIS | Patient Global Improvement Scale |
| Phys-SFR | physicians rating of sexual functioning |
| PSD | poststroke depression |
| px | prescription |
| QLDS | Quality of Life in Depression Scale |
| Q-LES-Q | Quality of Life Enjoyment and Satisfaction Questionnaire |
| QLSQ | Q-LES-Q |
| QOL | quality of life |
| QRS | time of ventricular contraction |
| QTcF | Fridericia-corrected time of ventricular contraction |
| RCT | randomized controlled trial |
| RD | Risk difference |
| RNZCGP | Royal New Zealand College of General Practitioners |
| RR | relative risk |
| RRR | relative risk ratio |
| SCID | Structured Clinical Interview for DSM-III Revised |
| SD | sexual dysfunction |
| SDS | Self rating Depression Scale |
| SDS | Sheehan Disability Scale |
| SER | sertraline |
| SF-36 | Medical Outcomes Study Health Survey - Short Form 36 |
| Sig | significant/significantly |
| SIP | Sickness Impact Profile |
| SSRI | selective serotonin reuptake inhibitor |
| TCA | tricyclic antidepressant |
| TMT-A | Trail Making Test - Part A |
| TMT-B | Trail Making Test - Part B |
| TRA | Trazodone |
| UK | United Kingdom |
| UKU | Utvalg for Kliniske Undersogelse (Side Effect Scale) |
| US | United States |
| USA | United States of America |
| UT | Utah |
| VAS | visual analog scale |
| VASC | patients with a history of cardiovascular illness (excluding hypertension) |
| VEN ER | venlafaxine extended release |
| VEN XR | venlafaxine extended release |
| VEN | venlafaxine |
| VF | verbal fluency test |
| vs. | versus |
| WHO | World Health Organization |
| wk | week(s) |
| WMS | Wechsler Memory Scale |
| yr | year(s) |
- Evidence Tables - Comparative Effectiveness of Second-Generation Antidepressants...Evidence Tables - Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
Your browsing activity is empty.
Activity recording is turned off.
See more...